ClassID:

20483

A61K31/603 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal

Recent Application in this class:
#1
20260053839
2026-02-26

COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS

#2
20250275986
2025-09-04

COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT

#3
20250228778
2025-07-17

PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION

#4
20250222011
2025-07-10

DRUG TARGET FOR INHIBITING TUMOR, USE, AND ORAL DRUG

#5
20240299293
2024-09-12

Oral rinse, nasal spray and methods for prevention of COVID-19 by lowering viral load of COVID-19

#6
20240226034
2024-07-11

Use of Terpenoids and Salicylates as Anesthetics and Analgesics

#7
20240201204
2024-06-20

Biomarker and Druggable Target of Neurodegeneration

#8
20240075052
2024-03-07

COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS

#9
20230064685
2023-03-02

METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA

#10
20220362265
2022-11-17

THERAPY

#11
20220362260
2022-11-17

METHODS OF TREATING LIPEDEMA INCLUDING AKR1C1 AS A THERAPEUTIC TARGET

#12
20210361692
2021-11-25

Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

#13
20210244677
2021-08-12

Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug

#14
20210236520
2021-08-05

METHODS FOR TREATING AND PREVENTING NOCICEPTIVE PAIN

#15
20210177758
2021-06-17

Platform drug delivery system utilizing crystal engineering and theanine dissolution

#16
20210069139
2021-03-11

STABILIZATION OF TRANSTHYRETIN TETRAMERS IN BIOLOGICAL FLUIDS

#17
20200390733
2020-12-17

Therapy for transthyretin-associated amyloidosis

#18
20200352895
2020-11-12

Compositions and methods of use of phorbolesters

#19
20200197418
2020-06-25

COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION

#20
20200138760
2020-05-07

Therapy for transthyretin-associated amyloidosis

#21
20200121697
2020-04-23

METHODS FOR DIAGNOSING AND TREATING CACHEXIA

#22
20200009119
2020-01-09

Methods and compositions to inhibit symptoms associated with veisalgia

#23
20200000755
2020-01-02

TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS

#24
20190350907
2019-11-21

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95- MEDIATED CELL MOTILITY

#25
20190224211
2019-07-25

Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection

#26
20190183837
2019-06-20

Compositions and methods of use of phorbolesters

#27
20190091188
2019-03-28

Therapy for transthyretin-associated amyloidosis

#28
20180207180
2018-07-26

Methods for treating and preventing nociceptive pain

#29
20180179596
2018-06-28

HISTONE MODIFICATION AGENTS FOR CANCER TREATMENT

#30
20180064649
2018-03-08

PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION

#31
20170319533
2017-11-09

Compositions and methods of use of phorbol esters

#32
20170304243
2017-10-26

Therapy for transthyretin-associated amyloidosis

#33
20160367565
2016-12-22

Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection

#34
20160317470
2016-11-03

Agent for inhibiting odor of pyrazine derivatives

#35
20160287613
2016-10-06

SALICYLATES FOR USE IN THE TREATMENT OF CANCER

#36
20160279112
2016-09-29

Methods and compositions to inhibit symptoms associated with veisalgia

#37
20160250173
2016-09-01

Compositions and methods of use of phorbol esters

#38
20160120883
2016-05-05

Anti-infective hydroxy-phenyl-benzoates and methods of use

#39
20150239830
2015-08-27

Class II HMG-CoA reductase inhibitors and methods of use

#40
20150238567
2015-08-27

Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy

#41
20150182434
2015-07-02

COSMETIC USE OF NAPTHOIC ACID DERIVATIVES

#42
20150017267
2015-01-15

Treatment of inflammatory disorders in non-human mammals

#43
20140329780
2014-11-06

INHIBITOR OF COLONISATION OF MUCOSA

#44
20140329740
2014-11-06

Anti-infective hydroxy-phenyl-benzoates and methods of use

#45
20140303074
2014-10-09

Compositions and Methods For Inhibiting Immunodeficiency Virus Transcription

#46
20140296188
2014-10-02

Therapy for transthyretin-associated amyloidosis

#47
20140163072
2014-06-12

Method, composition and kit for treating frequent headaches

#48
20140017196
2014-01-16

Compositions and methods of use of phorbol esters

#49
20130210775
2013-08-15

AGENT FOR INHIBITING ODOR OF PYRAZINE DERIVATIVES

#50
20120101021
2012-04-26

COMPOSITIONS, FORMULATIONS AND METHODS OF TREATING PREECLAMPSIA-TYPE DISORDERS OF PREGNANCY

#51
20120040888
2012-02-16

Anti-infective hydroxy-phenyl-benzoates and methods of use

#52
20110237546
2011-09-29

Method for treating a mammal by administration of a compound having the ability to release CO

#53
20100305152
2010-12-02

Method of inhibiting the growth of

#54
20100286222
2010-11-11

USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO SYNERGIZE ACTIVITY OF COX AND 5-LOX INHIBITORS

#55
20100081631
2010-04-01

METHODS AND COMPOSITIONS FOR TREATING GASTROINTENSTIAL DISORDERS

#56
20080070958
2008-03-20

Therapeutic Agent for Keratoconjunctival Disorder

#57
20080014252
2008-01-17

TOPICAL COMPOSITIONS WITH LONG LASTING EFFECT

#58
20070219120
2007-09-20

Methods for treating inflammatory disease by administering aldehydes and derivatives thereof

#59
20060293390
2006-12-28

Diflunisal for the treatment of cancer

#60
20060233890
2006-10-19

Method for treating a mammal by administration of a compound having the ability to release CO

#61
20060178347
2006-08-10

Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors

#62
20060166901
2006-07-27

Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids

#63
20060148900
2006-07-06

Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof

#64
20060069161
2006-03-30

Methods and reagents for the treatment of metabolic disorders

#65
20060057198
2006-03-16

Drug delivery from embolic agents

#66
20050112021
2005-05-26

Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light

#67
20050107347
2005-05-19

Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders

#68
15996937
2020-02-18

Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection